The SPRINT Data Analysis Challenge


    • Internal Medicine
    • Clinical Informatics
    • structural biology
    • data science
    • pharmacology
    • pharmacogenomics
    • Biomedical informatics
    General Internist and biomedical informatician at Stanford University
    General Internist and biomedical informatician at Stanford University
    • Bioinformaticist; Professor of Bioengineering, Genetics, Medicine, and Biomedical Data Science at Stanford University

    Dr. Russ Biagio Altman is a general internist and biomedical informatician. He is a Professor of Bioengineering, Genetics, Medicine, and Biomedical Data Science (and of Computer Science, by courtesy) and the Past Chairman of the Bioengineering Department at Stanford University.

    Russ’ studies involve human genetic variation impacts on drug response, as well as the analysis of biological molecules to understand actions, interactions, and adverse events of drugs. Recipient of the U.S. Presidential Early Career Award for Scientists and Engineers and a National Science Foundation CAREER Award, he has chaired the Science Board advising the FDA Commissioner, and currently serves on the NIH Director’s Advisory Committee and is Co-Chair of the IOM Drug Forum. He is an organizer of the annual Pacific Symposium on Biocomputing, and a founder of Personalis, Inc.  

    To learn more, visit 

  •  Paul Costello is a communications executive from California.  He has held posts such as press spokesman at the White House, the Ohio Governor’s office and the Mayor’s office in Washington, D.C.  In the private sector, he was vice president of public affairs at the cable channel, HBO and managing director of the New York office of the global public relations company, Weber Shandwick.  He was a patient participant in the SPRINT Trial.

    • Cardiovascular Disease
    • Director of the Division of Cardiology at McMaster University at McMaster University

    Dr. PJ Devereaux is a clinical trialist. He is the Director of the Division of Cardiology at McMaster University, and the Scientific Leader of the Anesthesiology, Perioperative Medicine, and Surgical Research Group at the Population Health Research Institute. 

    PJ’s major research interest is in vascular complications around the time of surgery. He has been an investigator on many trials such as CORONARY and HOPE-3, and has led or co-led major cardiovascular trials such as VISION and POISE-2. 

    To learn more, visit  


    Dr. Michael Eisen is a biologist at the University of California Berkeley and an Investigator of the Howard Hughes Medical Institute. Michael’s research encompasses evolution, development, genetics, genomics, chemical ecology and behavior, and, in his youth, he was a major contributor to the development and application of gene-chip microarrays. He is a strong proponent of open science, and a co-founder of the Public Library of Science.


    To learn more, visit



    Dr. Freda Lewis-Hall is a clinical trialist and patient advocate. She is the Chief Medical Officer of Pfizer and has held leadership roles in academia, medical research, front-line patient care, and at global biopharmaceutical companies including Vertex, Bristol-Myers Squibb and Eli Lilly. Trained as a psychiatrist, Freda launched her medical career in frontline patient care, becoming well known for her work on the effects of mental illness on families/communities and on the issues surrounding health care disparities. Prior to her work in industry, she led research projects for the National Institutes of Health and was Vice Chairperson of the Department of Psychiatry at Howard University College of Medicine.


    To learn more, visit


    • Infectious Disease
    • Global Health
    • Pediatrics
    • Clinical Trials
    • Critical Care
    Global Health; Imperial College, UK
    Global Health; Imperial College, UK

    Dr. Maitland is a clinical trialist. She is the Professor of Paediatric Tropical Infectious Diseases at the Faculty of Medicine, and the Director of the ICCARE Centre at the Global Centre of Health Innovation at Imperial College, London.

    Over the last 16 years, she has been based full-time in East Africa leading a clinical trials group whose major research portfolio includes severe malaria, bacterial sepsis, and severe malnutrition in children. Overseeing the largest trial of critically ill children ever undertaken in Africa, her team examined fluid resuscitation strategies in children with severe febrile illness, with surprising results showing fluid boluses increase mortality.  

    To learn more, visit

    Dr. Pajewski is a biostatician. He is the Assistant Professor in the Department of Biostatistical Sciences at Wake Forest School of Medicine and a Co-Investigator for the Systolic Blood Pressure Intervention Trial (SPRINT).

    Nick leads the statistical efforts at the Data Coordinating Center for the cognitive component of SPRINT, as well as for the Geriatrics Working Group.

    To learn more, visit

  • Dr. Michael Rosenblatt is a clinical trialist. He is the Chief Medical Officer of Flagship Ventures and the former EVP and CMO at Merck & Co, where he co-led the worldwide development team for alendronate (FOSAMAX), Merck's bisphosponate for osteoporosis and bone disorders.

    An endocrinologist by training, Michael has served as a founding scientist, scientific advisory board member, or director for more than a dozen biopharmaceutical companies, including ProScript, Millennium, Human Genome Sciences, and Radius Pharmaceuticals. He has provided congressional testimonies and served as a consultant to the U.S. President's Council of Advisors on Science and Technology.

    To learn more, visit


  • Originally from Nashville, TN, Moses Taylor graduated from Vanderbilt University in mechanical engineering and later received an MBA from American University.  Moses began his career as a naval officer and later entered the commercial energy industry where he continues to work as a mechanical engineer.  He is currently a Senior Associate at an engineering consulting firm in San Jose, CA where he has lived for the past 36 years.  Married with two adult children and three grandchildren, Moses is active in his local church and enjoys singing in a local community chorale that performs locally and internationally.  He was a participant in the SPRINT trial.


    • Health Policy Evidence Based Public Health
    • Health Policy
    • biotechnology policy
    • Bioethics
    • comparative effectiveness analysis
    • Macular Degeneration
    • public policy
    • genetics
    • Rare Diseases
    • Citizen Science
    • Advocacy
    Advocate/Activist/Citizen Scientist
    Advocate/Activist/Citizen Scientist

    Sharon F. Terry is a health advocate. She is the President and CEO of Genetic Alliance, a civic enterprise that provides resources to improve health and to further research. She is also the Co-Founder of PXE International, a research advocacy organization, established in response to the diagnosis of the genetic condition pseudoxanthoma elasticum (PXE) in her two children in 1994.

    Sharon is responsible for the co-discovery of the ABCC6 gene, patented in 2000 to ensure ethical stewardship. She subsequently developed a diagnostic test and conducts clinical trials. She is a member of the Advisory Group for the Precision Medicine Initiative, and the Blue Ribbon Panel’s Working Group on Enhanced Data Sharing for the Cancer Moonshot. She is an Ashoka Fellow.

    To learn more, visit


    Dr. Ramakrishna Rao Uppaluri is a retired scientist and a patient in the SPRINT program. He started his career in the Nuclear Magnetic Resonance division of the Tata Institute of Fundamental Research, Mumbai, India, where he worked on sodium amalgams and other alloys. In 1967, he joined the Bhabha Atomic Research Center (BARC), also in Mumbai, to work in the field of Materials Science. His 37 year scientific career spanned research in the areas of nmr of uncommon nuclei, Thermal Analysis, High Tc Compounds, Miscellar  Solutions and Nuclear Waste Management.  He is the author of 76 publications in peer-reviewed journals. In addition to his research activities, he also supervised 6 Doctoral students from University of Bombay. He retired from BARC as Head, Structural Inorganic Chemistry Section, in 1995.


  • Dr. Greet Van den Berghe is a clinical trialist. She is the Head of the Department & Laboratory of Intensive Care Medicine at the KU Leuven at the University of Leuven in Belgium, a large intensive care tertiary center treating over 3100 adult and pediatric patients each year.

    Greet is also a full Professor of Medicine at the KU Leuven, and has been running an active research program on the endocrinology of critical illness since 1995. She has published more than 360 papers in peer-reviewed journals (H-index: 65), and has authored many chapters in international textbooks on intensive care and endocrinology.

    To learn more, visit

    • Pulmonary Disease
    • at University of Pittsburgh

    Dr. Sally Wenzel is a clinical trialist. Currently serving as the Director of the University of Pittsburgh Asthma Institute at UPMC, she also holds the UPMC Chair in Translational Airway Biology and is the Subsection Chief of Allergy.

    Sally has a passion for understanding and improving the treatment of asthma, in particular severe asthma. Her studies of asthma phenotypes have led the field in understanding these complexities, including developing a strong translational program to study the pathobiology of severe asthma and its phenotypes, modeling ex vivo findings in vitro, and using primary human airway cells from patients and controls.

    To learn more, visit

    • Clinical Trials
    • coalition building
    • public policy
    • public opinion
    • advocacy
    I work for you -- for everyone who cares about driving medical progress through research and innovation
    I work for you -- for everyone who cares about driving medical progress through research and innovation

    Mary Woolley is a medical and health research advocate. She is the President of Research!America, the nation’s largest not-for-profit alliance working to make research and innovation a higher national priority. She is an elected member of the National Academy of Medicine (formerly the Institute of Medicine) and has served two terms on its Governing Council. Mary is a Fellow of the American Association for the Advancement of Science (AAAS) and has served two terms on the National Academy of Sciences Board on Life Sciences.

    In her early career, she served as San Francisco Project Director for the then largest-ever NIH-funded clinical trial, the Multiple Risk Factor Intervention Trial (MRFIT). In 1981, she became administrator of the Medical Research Institute of San Francisco, and in 1986, she was named the Institute's Executive Director and CEO.

    To learn more, visit

    • University
    • Associate Professor at University of Waterloo

    Dr. Leilei Zeng is a biostatistician. She is an Associate Professor in the Department of Statistics and Actuarial Science at the University of Waterloo. Her research interests involve the development of statistical methodology for the broad areas of longitudinal data analysis, time to event data analysis, and the design of clinical trials. Much of this work has been motivated by direct applications to important practical problems in biostatistics, public health and medical research.

    Leilei’s current research focus includes multi-state analysis of disease processes, design of clinical trials with composite endpoints and intermittent assessments, response dependent sampling, and incomplete observation of life history studies.

Want to stay updated? Follow Contest & Create Submissions